Turning Killers into THINKers: TME Hostility-Impervious NK Cells for Treating Neuroblastoma and Sarcoma |
Baylor College of Medicine / Robin Parihar, MD/PhD |
'A' Award Grants |
2021 |
Texas |
Prognostic and Therapeutic Significance of Stem Cell Heterogeneity in AML |
Fred Hutchinson Cancer Research Center / Roland Walter, MD, PhD |
'A' Award Grants |
2012 |
Washington |
Epigenetic Modifiers as Therapeutic Targets in Pediatric T-cell Acute Lymphoblastic Leukemia |
Washington University / Grant Challen, PhD |
'A' Award Grants |
2012 |
Missouri |
The Role of Inherited MLL3 Single Nucleotide Variants and Fetal Epigenetic Programming in Infant Leukemogenesis |
Washington University / Jeffrey Magee, MD/PhD |
'A' Award Grants |
2016 |
Missouri |
WWOX as a Signal Mediator in Pediatric Osteosarcoma |
The Ohio State University / Rami Aqeilan |
'A' Award Grants |
2009 |
Ohio |
Functional Characterization of RELA Fusion Ependymoma as a Basis for Therapeutic Targeting |
St. Jude Children’s Research Hospital / Stephen Mack, PhD |
'A' Award Grants |
2018 |
Tennessee |
Rational Combination Therapy of AML |
Memorial Sloan-Kettering Cancer Center / Alex Kentsis, MD, PhD |
'A' Award Grants |
2013 |
New York |
An Engineered Nanoimmunotherapy for Treating Neuroblastoma |
George Washington University / Rohan Fernandes, PhD |
'A' Award Grants |
2016 |
District of Columbia |
Exploiting the Differentiation Potential of Pediatric High-Grade Glioma to Discover Novel Therapeutic Opportunities |
Dana-Farber Cancer Institute / Mariella Filbin, MD/PhD |
'A' Award Grants |
2019 |
Massachusetts |
Genetically Modified, Cord Blood Derived Natural Killer Cell Therapy for High Grade Pediatric Brain Tumors |
Children’s Research Institute / Conrad Russell Cruz, MD, PhD |
'A' Award Grants |
2015 |
District of Columbia |